Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Champions Oncolog (CSBR)

Champions Oncolog (CSBR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 89,203
  • Shares Outstanding, K 11,615
  • Annual Sales, $ 20,240 K
  • Annual Income, $ -1,480 K
  • 60-Month Beta 1.07
  • Price/Sales 4.00
  • Price/Cash Flow N/A
  • Price/Book 38.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 07/31/19
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 0.04
  • Growth Rate Est. (year over year) +2,497,400.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.45 +0.40%
on 07/22/19
9.20 -18.70%
on 07/15/19
-1.03 (-12.10%)
since 06/21/19
3-Month
7.45 +0.40%
on 07/22/19
10.44 -28.35%
on 06/05/19
-0.74 (-9.00%)
since 04/22/19
52-Week
6.86 +9.04%
on 12/21/18
17.90 -58.21%
on 10/01/18
-1.28 (-14.61%)
since 07/20/18

Most Recent Stories

More News
Champions Oncology Reports Record Quarterly Revenue of $7.7 Million For The Fourth Quarter Ended April 30, 2019

CSBR : 7.48 (-2.60%)
Champions Oncology to Announce Fourth Quarter Financial Results on Monday, July 15, 2019

HACKENSACK, NJ / ACCESSWIRE / July 12, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development...

CSBR : 7.48 (-2.60%)
Moving Average Crossover Alert: Champions Oncology

Champions Oncology, Inc. (CSBR) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

CSBR : 7.48 (-2.60%)
New Strong Sell Stocks for April 16th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

ALK : 62.87 (-0.98%)
CCRN : 9.02 (+1.23%)
BMRN : 81.60 (+0.04%)
EXTN : 12.33 (+1.40%)
CSBR : 7.48 (-2.60%)
New Strong Sell Stocks for April 1st

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

CRON : 14.69 (-1.87%)
DF : 1.18 (+0.85%)
BGG : 9.49 (-1.66%)
BIOS : 2.87 (+0.70%)
CSBR : 7.48 (-2.60%)
New Strong Sell Stocks for March 27th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

BUD : 94.97 (+0.73%)
AEIS : 56.88 (+2.38%)
BMRN : 81.60 (+0.04%)
CSBR : 7.48 (-2.60%)
ASIX : 25.01 (+0.64%)
New Strong Sell Stocks for March 25th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

CNCE : 10.58 (-1.58%)
CCRN : 9.02 (+1.23%)
AEGN : 18.21 (+1.56%)
VNET : 7.17 (+0.42%)
CSBR : 7.48 (-2.60%)
Champions Oncology Reports Quarterly Revenue of $6.4 Million

CSBR : 7.48 (-2.60%)
Champions Oncology to Announce Third Quarter Financial Results on Monday, March 18, 2019

HACKENSACK, NJ / ACCESSWIRE / March 6, 2019 / Champions Oncology, Inc. (NASDAQ: CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development...

CSBR : 7.48 (-2.60%)
Champions Oncology (CSBR) Q3 Earnings: What's in Store?

During Champions Oncology's (CSBR) third-quarter fiscal 2019 conference call, investor focus will be on the company's progress with its Ex Vivo platform and services.

CTLT : 54.94 (+1.18%)
BDSI : 3.81 (unch)
TLRY : 42.20 (-3.19%)
CSBR : 7.48 (-2.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade CSBR with:

Business Summary

Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc., engages in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company's Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the...

See More

Key Turning Points

2nd Resistance Point 7.96
1st Resistance Point 7.72
Last Price 7.48
1st Support Level 7.34
2nd Support Level 7.21

See More

52-Week High 17.90
Fibonacci 61.8% 13.68
Fibonacci 50% 12.38
Fibonacci 38.2% 11.08
Last Price 7.48
52-Week Low 6.86

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar